Data brokers beware, the Securities Exchange Commission (SEC) has signaled increased scrutiny into the data and privacy practices of technology-enabled companies in the financial services industry. On September 14, the SEC announced that it settled a securities fraud investigation into private technology company App Annie, Inc. and its former CEO and Chairman Bertrand Schmidt, in
Over the summer of 2021, we have seen increased attention from the U.S. Securities and Exchange Commission (SEC) toward trading in cryptocurrency and other crypto assets. In particular, public comments by SEC Chair Gary Gensler have indicated that the SEC will soon take action against what he has described as the financial “Wild West.”[1]
On July 23, Oklahoma Governor Kevin Stitt named John O’Connor, 66, to the post of attorney general. O’Connor replaces Dawn Cash, who served as acting attorney general following Mike Hunter’s resignation at the end of May for personal reasons.
O’Connor will serve until the end of Hunter’s term in January 2023 and has confirmed that
FTC’s ‘Nixing the Fix’ Offers Insight Into Ramifications of Presidential Directive
Introduction
Regulators are increasingly interested in transactions related to consumer technology. For example, hybrid transactions involving the purchase and sale of Internet of Things (IoT) devices is one area ripe for regulatory oversight and enforcement as detailed in our prior article, “Regulators Likely
RICHMOND, Va. – Troutman Pepper’s Regulatory Practice Group, one of the country’s oldest practices dedicated solely to defending against enforcement actions from state attorneys general and other government authorities, launched today its regulatory law blog, Regulatory Oversight.
Regulatory Oversight will provide in-depth analysis into regulatory actions by various state and federal regulatory authorities, including
Over the past several years, the Democratic commissioners of the U.S. Federal Trade Commission (FTC) have made clear their dissatisfaction with the agency’s historic treatment of pharmaceutical mergers. Now, it appears that the FTC has launched a process aimed at changing the way in which such transactions are analyzed and ultimately resolved.
Past dissenting statements